Clinical Trial Update: Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab with S-1 and oxaliplatin as neoadjuvant therapy for advanced gastric cancer and advanced gastroesophageal junction adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN